Compare Pfizer Inc (PFE) vs Unilever plc (UL) Price & Performance

Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.

Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.

Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $1.83, narrowly missing the $1.84 estimate, continuing a trend of recent misses. Financially, UL maintains strong profitability with an 18.32% net income margin and 54.56% ROE, though revenue declined to $50.5B in 2025. Analyst sentiment is divided with a Hold consensus, while news highlights strategic shifts including the planned food business merger with McCormick.

The outlook balances high profitability and emerging market exposure against execution risks from portfolio restructuring and recent earnings misses. The stock's valuation at a P/E of 21.32 appears reasonable relative to historical margins, but investor caution is warranted given the bearish technical trend and regulatory scrutiny of the McCormick deal. Upside potential hinges on successful integration and volume growth sustainability.